MedAdvisor Limited: Transforming for Sustainable U.S. Growth

MedAdvisor Limited (ASX: MDR) reported a 52.8% decline in revenue to AU$9.6 million for 1Q FY26, impacted by regulatory delays, U.S. government pricing reforms, and ongoing financial pressures across the pharmacy sector. Despite this, the company achieved a strong net cash position of AU$13 million following the AU$35 million sale of its ANZ operations to Jonas Software AUS, leaving it debt-free.

The firm’s U.S. Transformation 360° program—now 80% complete—is designed to modernize its AI-driven patient engagement platform and reduce FY26 operating expenses by at least 15%. While vaccine program revenue dropped 90% year-over-year due to policy shifts, specialty and general medication segments are expected to recover in 2Q–3Q FY26. With a U.S. pipeline exceeding US$100 million, MedAdvisor is refocusing on innovation, AI integration, and partnership expansion to enhance profitability and long-term shareholder value.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com